View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 15, 2020

FibroGen: The company attempting to treat pneumonia in Covid-19 patients

By Jamie Bell

In its attempt to provide treatments for Covid-19 patients, American biopharma firm FibroGen has chosen to tackle the infection slightly differently to many of its peers in the industry.

Antivirals such as Gilead’s remdesivir and anti-inflammatory medicines like the chloroquine drug currently being taken by US president Donald Trump have drawn much of the mainstream media attention regarding coronavirus treatments thus far.

But FibroGen is instead trying to treat the symptoms of pneumonia — often seen in severely ill Covid-19 patients — using its antibody drug pamrevlumab.

Read the full article here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena